Imagion Biosystems Limited (IBXXF)
| Market Cap | 3.11M +20.6% |
| Revenue (ttm) | 396.56K -45.7% |
| Net Income | -3.20M |
| EPS | -0.01 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 400,000 |
| Open | 0.0120 |
| Previous Close | 0.0300 |
| Day's Range | 0.0120 - 0.0120 |
| 52-Week Range | 0.0100 - 0.0400 |
| Beta | -0.20 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 11, 2026 |
About Imagion Biosystems
Imagion Biosystems Limited operates as a medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases in Australia. The company is involved in nanotechnology; biotechnology; medical imaging using magnetic resonance; and cancer diagnostics businesses. It develops MagSense, which is in Phase 2 for the treatment of HER2 breast cancers, as well as advancing the research and development programs for prostate and ovarian cancer. It also develops PrecisionMRX, an iron oxide nanoparticle to magnetic relaxometry.... [Read more]
Financial Performance
In 2025, Imagion Biosystems's revenue was 73,031, a decrease of -97.26% compared to the previous year's 2.67 million. Losses were -4.31 million, 108.5% more than in 2024.
Financial numbers in AUD Financial StatementsNews
Medical-imaging company Imagion Biosystems Lodges IND with FDA for Phase 2 Trial of MagSense® HER2 targeted imaging agent
MELBOURNE, Australia--(BUSINESS WIRE)---- $IBX #FDA--Imagion Biosystems, Ltd. announced that the company has lodged an IND application with the FDA for its MagSense® targeted imaging agent.